# Module A: Forcing-Incident Reconstruction Report

## Executive Summary

- **Audit Scope**: 46 Historical Item Pairs (Part A: 1–31, Part B: 32–46) from `Archive/root-cleanup-2026-06-26/GEMINI-COHERENCE-CROSS-PRODUCT-SPEC.md`.
- **Reviewing Model**: Gemini 3.7 Flash (`gemini-3.7-flash`, High capability tier).
- **Total Pairs Evaluated**: 46
- **Verdict Breakdown**:
  - `RECONCILABLE`: 22 pairs (47.8%)
  - `NO_SHARED_DECISION`: 24 pairs (52.2%)
  - `CONTRADICTION`: 0 pairs (0.0%)
- **Audit Mode**: Strict Blinded Clinical Reconstruction under Work Order §3.2 isolation invariants.

## Methodological Synthesis

Each candidate pair was evaluated under a closed-world clinical judgment model comparing the exact rules, keys, rationales, and option payloads. Pairs were categorized into three principal groupings:

1. **Pharmacology, Triage, and Nursing Procedures (`RECONCILABLE`)**:
   - **Anticoagulation & Antiplatelet Safety** (Pairs 4, 10): Distinguishes routine laboratory requirements across classes (UFH requiring aPTT vs DOACs not requiring routine monitoring) and specific adverse effect triggers (HIT, major hemorrhage).
   - **Asthma Acuity & Decompensation** (Pair 5): Unifies expected moderate distress manifestations against indicators of ventilatory failure (silent chest, severe hypercapnia, inability to speak).
   - **Neonatal Assessment & Temperature Regulation** (Pair 6): Fully harmonizes expected 24-hour findings (acrocyanosis) with cold stress indicators (axillary temperature 96.8 °F [36.0 °C]).
   - **Postoperative Wound Healing & Complications** (Pairs 7, 8, 9): Reconciles expected early serous/serosanguineous exudate with wound dehiscence, surgical site infections, or procedure-specific complications (thyroidectomy airway compromise).
   - **Metformin Periprocedural Safety** (Pair 11): Harmonizes 48-hour withholding rules and renal clearance monitoring (creatinine/eGFR) around iodinated contrast dye.
   - **Postpartum Uterine Atony Triage** (Pair 12): Establishes the clinical distinction between lateral fundal displacement (indicating bladder distension where voiding precedes massage) and midline atonic hemorrhage (where bimanual fundal massage and uterotonics are immediate priorities).
   - **Clozapine Toxicity Surveillance** (Pairs 26, 27, 28): Unifies outpatient patient education regarding infection warning signs with inpatient management of febrile neutropenia and clozapine-induced myocarditis.
   - **Opioid Reversal** (Pair 29): Complete agreement on recognizing severe opioid respiratory depression and administering naloxone.
   - **HIPAA Privacy & Disclosure Standards** (Pairs 30, 31): Harmonizes permitted care-coordination disclosures against unauthorized third-party disclosures or unverified transmissions.
   - **Coronary Artery Territory & Dysrhythmia Patterns** (Pair 39): Reconciles anterior LAD STEMI (tachycardia, V1–V4 ST elevation) with inferior RCA MI (bradycardia, AV nodal blocks, RV involvement, vagal nausea).
   - **Pressure Injury Staging, Prevention, and Care Planning** (Pairs 40, 41, 42, 44, 45, 46): Enforces uniform NPUAP/EPUAP staging definitions (Stage 3 vs Unstageable thick eschar) and evidence-based multi-modal prevention protocols (q2h turning, heel floating, pressure redistribution surfaces; strict contraindication against massaging reddened bony prominences).

2. **Format-Driven Co-Occurrences (`NO_SHARED_DECISION`)**:
   - **Dosage Calculations** (Pairs 1, 2, 3): Evaluated independent drug calculations with different weights, routes, and dosing parameters.
   - **Ordered Response Sequences** (Pairs 13, 14, 15): Evaluated independent clinical protocols (IV push technique vs med error response, telephone orders, and hypoglycemia).
   - **Cluster Matched Items** (Pairs 16–25, 32–38, 43): Items matched by topical labels or case study container formats that address completely disparate clinical scenarios (e.g., CKD AV fistula care vs Pacemaker precautions, shock, central lines, blood transfusion, or thoracentesis).

## Pair-by-Pair Audit Table

| Pair # | Item A ID | Item B ID | Verdict | Confidence | Clinical Summary |
|:---:|:---|:---|:---:|:---:|:---|
| 1 | `claude_a_fib_amoxicillin_pediatric_15` | `fib_acetaminophen_tablets_027` | **NO_SHARED_DECISION** | HIGH | Different medications, routes of calculation, patient populations, and clinical indication... |
| 2 | `claude_a_fib_dopamine_drip_05` | `gpt_canonical_fib_heparin_rate_033` | **NO_SHARED_DECISION** | HIGH | Different drug classes, indications, concentration parameters, and dosing units (weight-ba... |
| 3 | `claude_a_fib_dopamine_drip_05` | `gpt_pharm_easy_medium_2026_06_21_a_fib_heparin_rate_01` | **NO_SHARED_DECISION** | HIGH | Different medications, clinical mechanisms, and concentration bags (dopamine inotrope vs h... |
| 4 | `claude_a_matrix_anticoagulant_monitoring_16` | `gpt_u6_matrix_cloze_2026_06_09_matrix_heparin_safety_11` | **RECONCILABLE** | HIGH | Item A classifies baseline routine monitoring indications across distinct anticoagulant cl... |
| 5 | `claude_a_matrix_asthma_06` | `gpt_canonical_matrix_asthma_exacerbation_065` | **RECONCILABLE** | HIGH | Distinction between presenting severity stages (moderate distress vs imminent respiratory ... |
| 6 | `claude_a_matrix_neonatal_assessment_46` | `gpt_canonical_matrix_newborn_findings_045` | **RECONCILABLE** | HIGH | Both items assess early transitional neonates (first 24 hours of life).... |
| 7 | `claude_a_matrix_wound_assessment_26` | `gpt_canonical_matrix_wound_assessment_077` | **RECONCILABLE** | HIGH | Both items evaluate clean surgical incision healing trajectories across early postoperativ... |
| 8 | `claude_a_matrix_wound_assessment_26` | `gpt_u6_matrix_cloze_2026_06_09_matrix_post_thyroidectomy_complications_03` | **RECONCILABLE** | HIGH | General surgical wound healing criteria (Item A) versus neck-surgery-specific postoperativ... |
| 9 | `claude_a_matrix_wound_assessment_26` | `matrix_postop_findings_028` | **RECONCILABLE** | HIGH | Incision-specific wound assessment (Item A) versus broad multi-system postoperative recove... |
| 10 | `claude_a_mc_dabigatran_teaching_03` | `mc_warfarin_bleeding_teaching_018` | **RECONCILABLE** | HIGH | Pharmacological distinction between direct-acting oral anticoagulants (DOACs, e.g., dabiga... |
| 11 | `claude_a_mc_metformin_contrast_13` | `gpt_deepen_2026_06_22_bow_10` | **RECONCILABLE** | HIGH | Standard clinical guideline execution (Item A) versus unit protocol execution with laborat... |
| 12 | `claude_a_mc_postpartum_fundus_41` | `gpt_canonical_cloze_postpartum_hemorrhage_044` | **RECONCILABLE** | HIGH | Clinical assessment distinction: a laterally displaced boggy fundus indicates bladder dist... |
| 13 | `claude_a_or_iv_push_safety_14` | `gpt_canonical_or_medication_error_084` | **NO_SHARED_DECISION** | HIGH | Different clinical workflows (routine aseptic IV push administration technique vs post-inc... |
| 14 | `claude_a_or_iv_push_safety_14` | `gpt_canonical_or_telephone_order_110` | **NO_SHARED_DECISION** | HIGH | Bedside drug administration sequence vs communication/order verification protocol (verbal/... |
| 15 | `claude_a_or_iv_push_safety_14` | `or_hypoglycemia_actions_026` | **NO_SHARED_DECISION** | HIGH | Parenteral medication administration procedure vs rule-of-15 acute hypoglycemia management... |
| 16 | `claude_a_sata_eps_haloperidol_12` | `gpt_case_clozapine_toxicity_01_q2` | **NO_SHARED_DECISION** | HIGH | Completely different antipsychotic drug classes, receptor binding profiles, and adverse ef... |
| 17 | `claude_a_sata_hf_discharge_02` | `gpt_case_gap_2026_06_11_community_resources_part_3_sata_actions` | **NO_SHARED_DECISION** | HIGH | Client disease-specific self-monitoring education (heart failure decompensation signs) vs ... |
| 18 | `claude_a_sata_hf_discharge_02` | `gpt_case_opus23_nat_toddler_01_q5` | **NO_SHARED_DECISION** | HIGH | Adult cardiology symptom reporting vs pediatric child-abuse safety planning and protective... |
| 19 | `claude_a_sata_hf_discharge_02` | `gpt_case_unsafe_premature_discharge_01_q4` | **NO_SHARED_DECISION** | HIGH | Client self-management teaching vs nursing advocacy against unsafe premature discharge.... |
| 20 | `claude_a_sata_hf_discharge_02` | `gpt_opus21_case_colostomy_lep_discharge_01_q2` | **NO_SHARED_DECISION** | HIGH | Medical symptom recognition in heart failure vs language-concordant surgical ostomy self-c... |
| 21 | `claude_a_sata_hf_discharge_02` | `gpt_opus21_case_colostomy_lep_discharge_01_q6` | **NO_SHARED_DECISION** | HIGH | Adult heart failure symptom education vs post-surgical ostomy language-access discharge co... |
| 22 | `claude_a_sata_mmr_vaccine_48` | `gpt_gap_2026_06_12_nonmcq_balanced_b_case_peds_dehydration_03_q5` | **NO_SHARED_DECISION** | HIGH | Pediatric routine immunization guidance vs acute pediatric viral gastroenteritis / dehydra... |
| 23 | `claude_a_sata_neonatal_jaundice_42` | `gpt_canonical_sata_breastfeeding_085` | **NO_SHARED_DECISION** | HIGH | Neonatal hyperbilirubinemia pathophysiology vs maternal lactation technique and feeding ad... |
| 24 | `claude_a_sata_neonatal_jaundice_42` | `gpt_canonical_sata_pregnancy_warning_signs_053` | **NO_SHARED_DECISION** | HIGH | Newborn jaundice assessment vs maternal prenatal complications (preeclampsia, placental ab... |
| 25 | `claude_a_sata_neonatal_jaundice_42` | `sata_newborn_safety_teaching_008` | **NO_SHARED_DECISION** | HIGH | Newborn metabolic/hematologic assessment vs newborn environmental safety and SIDS preventi... |
| 26 | `claude_jun05_pharm_clozapine_teaching_05` | `gpt_case_clozapine_toxicity_01_q2` | **RECONCILABLE** | HIGH | Outpatient preventative client education (Item A) versus acute inpatient recognition of ac... |
| 27 | `claude_jun05_pharm_clozapine_teaching_05` | `gpt_case_clozapine_toxicity_01_q4` | **RECONCILABLE** | HIGH | Patient-level warning education (Item A) versus emergency inpatient clinical intervention ... |
| 28 | `claude_jun05_pharm_clozapine_teaching_05` | `gpt_case_clozapine_toxicity_01_q6` | **RECONCILABLE** | HIGH | Baseline monitoring education (Item A) versus post-toxicity recovery tracking and rechalle... |
| 29 | `claude_jun05_pharm_pca_opioid_safety_04` | `gpt_canonical_cloze_opioid_safety_094` | **RECONCILABLE** | HIGH | Both items address opioid toxicity in postoperative clients receiving IV morphine.... |
| 30 | `claude_moc_hipaa_breach_hl_b03` | `gpt_deepen_2026_06_22_moc_01` | **RECONCILABLE** | HIGH | Both items apply federal HIPAA Privacy Rule standards (and NY-RN practice scope) across cl... |
| 31 | `claude_moc_hipaa_breach_hl_b03` | `gpt_deepen_2026_06_22_moc_11` | **RECONCILABLE** | HIGH | Verbal/physical information exposure breaches (Item A) versus electronic/fax transmission ... |
| 32 | `cs_ckd_01_q3` | `gemini_jun05_a_sata_pacemaker_41` | **NO_SHARED_DECISION** | HIGH | Chronic kidney disease hemodialysis vascular access care vs surgical cardiac implantable d... |
| 33 | `cs_ckd_01_q3` | `trad_batchD_08` | **NO_SHARED_DECISION** | HIGH | Outpatient chronic hemodialysis maintenance teaching vs acute circulatory shock compensato... |
| 34 | `cs_ckd_01_q3` | `trad_batchD_10` | **NO_SHARED_DECISION** | HIGH | Permanent peripheral hemodialysis arteriovenous fistula maintenance vs acute central venou... |
| 35 | `cs_ckd_01_q3` | `trad_batchD_20` | **NO_SHARED_DECISION** | HIGH | Chronic renal patient self-care instruction vs physical assessment of hypervolemic fluid o... |
| 36 | `cs_ckd_01_q3` | `trad_batchD_24` | **NO_SHARED_DECISION** | HIGH | Chronic renal disease access teaching vs acute transfusion reaction recognition and differ... |
| 37 | `cs_ckd_01_q5` | `gemini_c8_08` | **NO_SHARED_DECISION** | HIGH | Hemodialysis efficacy evaluation vs post-thoracentesis acute pleural complication triage.... |
| 38 | `claude_a_sata_tracheostomy_09` | `cs_ckd_01_q3` | **NO_SHARED_DECISION** | HIGH | Airway tracheostomy stoma nursing care vs vascular access maintenance in renal failure.... |
| 39 | `cs_stemi_vfib_04_part_1` | `gemini_b1_04` | **RECONCILABLE** | HIGH | Anatomical and pathophysiological distinction by coronary artery distribution: Anterior ST... |
| 40 | `claude_cs_jun06_pressure_injury_bcc_01` | `gpt_gap_2026_06_12_nonmcq_balanced_case_pressure_injury_nutrition_03` | **RECONCILABLE** | HIGH | Both are comprehensive case studies applying national/international pressure injury guidel... |
| 41 | `claude_cs_jun06_pressure_injury_bcc_01_part_2` | `gpt_canonical_matrix_pressure_injury_040` | **RECONCILABLE** | HIGH | Both items evaluate direct bedside nursing actions for pressure injury prevention and safe... |
| 42 | `claude_cs_jun06_pressure_injury_bcc_01_part_4` | `gemini_d8_10` | **RECONCILABLE** | HIGH | NPUAP staging definitions: Stage 3 requires visualization of subcutaneous fat without deep... |
| 43 | `claude_cs_jun06_pressure_injury_bcc_01_part_4` | `opus_bcc_rehab_2026_06_10_01` | **NO_SHARED_DECISION** | HIGH | Staging an established necrotic wound (Item A) versus prospective Braden Scale risk factor... |
| 44 | `claude_cs_jun06_pressure_injury_bcc_01` | `gpt_case_gap_2026_06_11_case_pressure_injury_ltc_04` | **RECONCILABLE** | HIGH | Acute/subacute inpatient pressure injury case study vs long-term care residential pressure... |
| 45 | `claude_cs_jun06_pressure_injury_bcc_01` | `gpt_case_premium_2026_06_10_case04_pressure_injury_rehab` | **RECONCILABLE** | HIGH | Both case studies follow clinical practice guidelines for pressure ulcer prevention and ma... |
| 46 | `claude_cs_jun06_pressure_injury_bcc_01_part_2` | `gpt_case_gap_2026_06_11_pressure_ltc_part_2_sata_plan` | **RECONCILABLE** | HIGH | Acute care prevention plan (Item A) versus long-term residential care prevention plan (Ite... |

